>latest-news

FDA Grants Fast-Track Status to Novo Nordisk’s Hemophilia Drug

Concizumab gains FDA fast-track for hemophilia treatment, speeding development and review process.

Breaking News

  • Oct 22, 2024

  • Mrudula Kulkarni

FDA Grants Fast-Track Status to Novo Nordisk’s Hemophilia Drug

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation for their new drug, concizumab, aimed at treating patients with hemophilia A and B. This designation is a significant step in speeding up the development and review process for therapies that address unmet medical needs.

Concizumab works as a monoclonal antibody, targeting the tissue factor pathway inhibitor (TFPI), which helps regulate blood clotting. This makes it a promising treatment for hemophilia patients.

Novo Nordisk is committed to advancing concizumab's clinical development to offer improved treatment options for those affected by hemophilia.

Ad
Advertisement